alterations,drugs,approvedIndications,level,fdaLevel,levelAssociatedCancerType,levelExcludedCancerTypes,pmids,abstracts,description
['Y1230H'],"[{'ncitCode': 'C74061', 'drugName': 'Crizotinib'}]",[],LEVEL_R2,LEVEL_Fda3,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],"['27666659', '28396313', '27987579', '29128427', '28522754']",[],"Capmatinib and crizotinib are small molecule inhibitors of MET that are FDA-approved and/or NCCN-listed for adult patients with metastatic non-small cell lung cancer (NSCLC) harboring MET alterations. Across multiple case reports, the MET Y1230H mutation was detected in four patients with MET exon 14-positive (D1010H) NSCLC after progression on crizotinib treatment and in one patient after progression on capmatinib (PMID: 27666659, 29128427, 28522754, 28396313, 27987579)."
['Y1230H'],"[{'ncitCode': 'C90564', 'drugName': 'Capmatinib'}]",[],LEVEL_R2,LEVEL_Fda3,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],"['27666659', '28396313', '27987579', '29128427', '28522754']",[],"Capmatinib and crizotinib are small molecule inhibitors of MET that are FDA-approved and/or NCCN-listed for adult patients with metastatic non-small cell lung cancer (NSCLC) harboring MET alterations. Across multiple case reports, the MET Y1230H mutation was detected in four patients with MET exon 14-positive (D1010H) NSCLC after progression on crizotinib treatment and in one patient after progression on capmatinib (PMID: 27666659, 29128427, 28522754, 28396313, 27987579)."
